*UPDATED 10/2022
Maybe you learned about the thyroid gland in health or anatomy and physiology class, but haven’t thought much else about it since your school days. This small but mighty part of our bodies plays a big role in our overall health, and there are important considerations for thyroid function during pregnancy. The thyroid gland, found near the lower part of the throat near the trachea, creates and produces thyroid hormones that are needed throughout many systems in the body. Those who have a thyroid producing too much or too little of these hormones have thyroid disease.
When the thyroid gland produces too much hormone, a condition called ‘hyperthyroidism’ is present. When there is too little hormone produced, it is known as ‘hypothyroidism’. Today, I’ll share the recent ACOG recommendations for thyroid disease in pregnancy so you can be better informed when it comes to your thyroid health and your pregnancy.
A diagnosis of hyperthyroidism with low thyroid stimulating hormone (TSH) and increased free T4 (FT4) is based on clinical symptoms and abnormal laboratory values. Hyperthyroidism occurs in 0.2-0.7% of pregnancies with Graves disease accounting for 95% of these cases. If left untreated during pregnancy, hyperthyroidism can potentially lead to preterm delivery, low birth weight, stillbirth, miscarriage, preeclampsia, maternal heart failure, and a potentially life-threatening condition called ‘thyroid storm’.
The management of a new diagnosis of hyperthyroidism in pregnancy generally follows these principles:
It is not ideal to use MMI in the first trimester due to its association with birth defects, including esophageal/choanal atresia and aplasia cutis. Due to the rare association of PTU with hepatotoxicity (toxicity to the liver), one may be given the option to transition to MMI or continue PTU after the first trimester.
A very rare (<1%) side effect with PTU or MMI treatment is agranulocytosis, which involves having an extremely low number of granulocytes in the blood. You should stay alert for sore throat or fever, and contact your healthcare provider immediately if they occur within 3 months of starting treatment of PTU or MMI.
Some patients will experience heart palpitations. If this occurs, a medication called propranolol may be given to help control symptoms.
Fetal thyrotoxicosis is when the fetus in utero develops a clinical state of high levels of circulating thyroid hormones (T3 and/or T4) in the body from any cause. Because of the persistence of maternal antibodies, the possibility of fetal thyrotoxicosis should be considered in all patients with a history of Graves disease. Signs of fetal thyrotoxicosis are fetal hydrops, fetal growth restriction, and fetal goiter that can be found on ultrasound or fetal tachycardia (high heart rate) that can be seen on ultrasound or in the clinic when assessing fetal heart rate.
The management of a new diagnosis of hypothyroidism in pregnancy is based on clinical symptoms and abnormal laboratory values. It occurs in 2-10 per 1,000 pregnancies.The most common type of hypothyroidism is Hashimoto thyroiditis where antithyroid peroxidase antibodies destroy the thyroid gland. Unlike in Graves disease, maternal antibodies rarely cross the placenta to affect the fetus. If left untreated, however, the potential outcomes for hypothyroidism are miscarriage, preeclampsia, preterm birth, abruption, stillbirth, low birth weight, and abnormal neuropsychological development in offspring.
The management of of a new diagnosis of hypothyroidism in pregnancy generally follows these principles:
Fetal central nervous system development is dependent on adequate maternal thyroid hormones. It is rare for maternal antibodies to cross the placenta and cause fetal hypothyroidism.
Subclinical hyperthyroidism is an abnormally low serum TSH concentration with free T4 levels within the normal ref range. It has not been associated with adverse pregnancy outcomes. Treatment of pregnant persons with subclinical hyperthyroidism is not recommended because there is no benefit to the patient or fetus.
Subclinical hypothyroidism is an elevated serum TSH level in the presence of a normal free T4 level. Again, there is no evidence that identification and treatment of subclinical hypothyroidism during pregnancy improves outcomes so no treatment is recommended.
The American College of Obstetricians and Gynecologists, the Endocrine Society, and the American Association of Clinical Endocrinologists recommend against universal screening for thyroid disease in pregnancy. They recommend testing during pregnancy only for patients who are at increased risk of overt hypothyroidism. Indicated testing of thyroid function should be performed in patients with a personal or family history of thyroid disease, type 1 diabetes mellitus, or clinical suspicion of thyroid disease. Speak with your physician if you feel like you are at risk for thyroid disease, have known thyroid disease, or have a family history of it. If you are not already working with an endocrinologist, your OBGYN might refer you to one.
Shannon M. Clark, MD, MMS is a double board certified ObGyn and Maternal-Fetal Medicine Specialist, and founder of Babies After 35. In her roles as a clinician, educator and researcher at UTMB-Galveston, she focuses on the care of people with maternal and/or fetal complications of pregnancy. Dr. Clark has taken a special interest in pregnancy after the age of 35, which according to age alone, is considered a high-risk pregnancy.
Follow Shannon on TikTok @tiktokbabydoc, Facebook @babiesafter35, and Instagram @babiesafter35.
Check out the products for TTC through parenthood in the Babies After 35 Amazon shop, online courses and other services that come "Dr. Clark-approved"!
Check out my favorite things